Author

A. Krokhotin

Primary ORCID profile (0009-0006-4435-3213 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

A. KrokhotiniD2 papers · Howard Hughes Medical Institute

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:proteomics· 1

Frequent Co-Authors

G. R. Crabtree· 2 shared J. M. Simanauskaite· 2 shared S. P. Gourisankar· 2 shared T. Zhang· 2 shared B. A. Karim· 1 shared B. Dwyer· 1 shared C.-y. Chang· 1 shared H. Abuzaid· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. R. Crabtree

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Borrowing Transcriptional Kinases to Activate Apoptosis

R. C. Sarott, S. P. Gourisankar, B. A. Karim, S. Nettles, H. Yang, B. Dwyer, J. M. Simanauskaite, J. Tse, H. Abuzaid, A. Krokhotin, T. Zhang, S. M. Hinshaw, M. R. Green, G. R. Crabtree, N. Gray

The paper develops bivalent molecules that convert kinase inhibitors into activators of proapoptotic genes, achieving selective killing of DLBCL cells with low cytotoxicity.

bioRxiv · Oct 23, 2023 · PreprintCancer Biology

Rewiring Cancer Drivers to Activate Apoptosis

S. P. Gourisankar, A. Krokhotin, W. Ji, X. Liu, C.-y. Chang, S. H. Kim, Z. Li, W. Wenderski, J. M. Simanauskaite, T. Zhang, N. S. Gray, G. R. Crabtree

This paper introduces TCIPs, molecules that activate cell death by rewiring cancer drivers, showing efficacy against DLBCL and potential for broader therapeutic applications.

Nature · Aug 10, 2023Peer-reviewedCancer Biology